Future research should explore long-term safety, efficacy in combination with SGLT2 inhibitors, and the role of multi-agonist therapies targeting GIP, glucagon, or amylin pathways
Recent studies support the hypothesis that autoimmune thyroiditis is tumorigenic in itself and that through excitation of the TSH receptor, HT-associated hypothyroidism may also contribute to tumor growth (Boi et al
Saxenda (liraglutide) is a brand-name glucagon-like peptide-1 (GLP-1) agonist made by the pharmaceutical company Novo Nordisk
and Ossianix, is another peptibody targeting neurodegenerative diseases such as Alzheimers disease
Researchers found that diabetes patients faced 4x increased NAION risk when using semaglutide, and weight loss patients showed an even higher 7x increased risk of this vision complication
These methodological flaws tend to limit the usefulness of the research